

McKenzie JA, Wilson-Clarke C, Prout J, Campbell J, Douglas RD, Gossell-Williams M. Improving warfarin therapy through implementation of a hospital-based pharmacist managed clinic in Jamaica. *Pharmacy Practice* 2018 Oct-Dec;16(4):1214. <https://doi.org/10.18549/PharmPract.2018.04.1214>

Original Research

Improving warfarin therapy through implementation of a hospital-based pharmacist managed clinic in Jamaica

Jodi-Ann MCKENZIE , Cameil WILSON-CLARKE , Jennifer PROUT , Jacqueline CAMPBELL ,
Rhea-Danielle DOUGLAS , Maxine GOSSELL-WILLIAMS .

Received (first version): 20-Feb-2018

Accepted: 14-Oct-2018

Published online: 7-Nov-2018

Abstract

Background: Pharmacist managed warfarin clinics can improve the anticoagulation status of non-valvular patients. The first of such services was implemented at the Cornwall Regional Hospital in Jamaica in 2013.

Objectives: To assess the anticoagulation control of patients on warfarin therapy over six months in the pharmacist managed warfarin clinic at Cornwall Regional Hospital.

Methods: Retrospective docket review for the period January 2014 to December 2016 was done to include data of patients attending routine clinic appointments for at least six months. Age, gender, date of visit, indication for warfarin therapy, warfarin dose and International Normalized Ratio readings were extracted. Percentage time spent in therapeutic range (TTR) was calculated by month for six months using the Rosendaal linear interpolation method. Patient anticoagulation status was categorized as poor (TTR<40%), moderate (TTR=40-64%) or good (TTR≥65%) and anticoagulation status at three months and six months was compared.

Results: For the period of assessment, 52 patients were identified; the median age was 58 years and 36 patients were males. Deep vein thrombosis was the main indication for therapy (22 of 52) and median warfarin weekly dose ranged was 15.0-130 mg. At time of recruitment most of the patients were outside the target INR range (43 of 52). Within one month, the median TTR attained was 31% [IQR 62-10]. This significantly improved by second month to 60% [IQR 82-23] ($p=0.001$). By month three, the proportion of patients in good, moderate and poor anticoagulant status was 19/51, 15/51 and 17/51 respectively, which at six months changed to 23/51, 12/51, 16/51 respectively; thus, although coagulation status improved from month one to three, there was no significant improvement from month three to month six ($p=0.31$).

Conclusions: The pharmacist managed warfarin clinic monitoring services were successful in attaining TTRs >40% and sustaining these values over six months. The services should therefore be encouraged.

Keywords

Program Evaluation; Warfarin; Anticoagulants; International Normalized Ratio; Pharmaceutical Services; Pharmacists; Retrospective Studies; Jamaica

INTRODUCTION

Warfarin remains a major choice for oral anticoagulation in non-valvular atrial fibrillation and deep vein thrombosis; however, anticoagulation status is impacted by many factors including dietary, ethnicity, genetics, age and weight.¹⁻⁴ To ensure adequate efficacy and safety with warfarin therapy, regular assessment is required to maintain an International Normalized Ratio (INR) within the recommended therapeutic range of 2.0 – 3.0, except for patients with mechanical heart valves or recurrent myocardial infarction, where the recommended range is 2.5–3.5.⁵

Optimising the percentage of time spent in therapeutic range for INR (TTR) can reduce the risk of haemorrhagic and thromboembolic events.^{6,7} Connolly *et al.*⁸ reviewed TTR data from anticoagulation centres of 15 countries and reported that a TTR of at least 65% is required for optimum benefit of warfarin therapy. This threshold forms part of the guidelines supported by the United Kingdom National Institute for Health and Care Excellence and the University of Nottingham PRIMIS development group⁹; furthermore these guidelines suggest that there is no benefit from warfarin therapy when TTR <40%.^{10,11}

Active monitoring through specialized anticoagulation clinics have proven beneficial in optimizing warfarin therapy and reducing the risk of complications.¹²⁻¹⁶ In a systematic review published in 2017 of 25 randomized controlled and observational studies of 12,252 patients receiving warfarin therapy, it was shown that anticoagulation status was significantly improved in pharmacist managed outpatient care facilities, including lower bleeding and thromboembolic events.¹⁷

At the first pharmacist managed anticoagulation clinic established in 2013 at the Cornwall Regional Hospital in Jamaica, patients are managed for INR control once warfarin therapy is initiated by physicians at the hospital. The role of the pharmacist assigned to the clinic include making dosage adjustments to warfarin therapy as needed, as well as teach patients on appropriate dietary practices

Jodi-Ann MCKENZIE. RPh, MSc. Section of Pharmacology & Pharmacy, Faculty of Medical Sciences, University of the West Indies, Mona Campus. Kingston (Jamaica). jodi-mack@hotmail.com
Cameil WILSON-CLARKE. PharmD. Section of Pharmacology & Pharmacy, Faculty of Medical Sciences, University of the West Indies, Mona Campus. Kingston (Jamaica). cameil.wilsonclarke@uwimona.edu.jm
Jennifer PROUT. RPh, PharmD. Cornwall Regional Hospital, Montego Bay (Jamaica). proutjennifer@yahoo.com
Jacqueline CAMPBELL. MBBS PhD. Section of Pharmacology & Pharmacy, Faculty of Medical Sciences, University of the West Indies, Mona Campus. Kingston (Jamaica). jacqueline.campbell02@uwimona.edu.jm
Rhea-Danielle DOUGLAS. Section of Pharmacology & Pharmacy, Faculty of Medical Sciences, University of the West Indies, Mona Campus. Kingston (Jamaica). ree.353@hotmail.com
Maxine GOSSELL-WILLIAMS. PhD. Section of Pharmacology & Pharmacy, Faculty of Medical Sciences, University of the West Indies, Mona Campus. Kingston (Jamaica). maxine.gossell@uwimona.edu.jm



with specific focus on vitamin K content. Possible drug interactions are also reviewed and changes actioned after consultation with assigned physician. The pharmacist initially measures INR weekly until target INR is attained and then appointments are moved to once monthly. The aim of this study was to assess the anticoagulation status achieved by this pharmacist managed clinic over a six month period of monthly monitoring.

METHODS

A retrospective review of patient records of the pharmacist managed warfarin clinic at the Cornwall Regional Hospital from the period January 2014 to December 2016 was done. The Cornwall Regional Hospital is a 400-bed capacity institution, providing many specialty services including Cardiology. The protocol was approved by the Ministry of Health Ethics Committee and the University of the West Indies Ethics Committee.

Only records of patients who were of at least 18 years old at first registration to the clinic and were on warfarin therapy for at least six months were selected. Six months was chosen as adequate to assess clinic performance based on a previous study evaluating anticoagulation clinics of the Veteran Affairs Health System in the United States of America.¹⁸ Records were excluded if patients were younger than 18 years, had severely impaired liver and kidney function, as well as patients with bleeding disorders such as hemophilia. Data extracted from the records included patient age, gender, indication for warfarin, warfarin dose at first visit and at each monthly visit, as well as the number of missed warfarin doses per week. The missed dose information was used as a measure of compliance with warfarin therapy. INR readings were also recorded from the patient records. These readings were obtained by the pharmacist at the each visit using the Roche Diagnostic CoaguChek XS Plus system; a validated point-of-care device that consists of a CoaguChek XS Plus monitor with CoaguChek XS Plus pro-thrombin test strips and produces results within seconds from a drop ($\geq 8\mu\text{L}$) of capillary blood. The test strip consist of lyophilized reagents, thromboplastin and a peptide substrate and has an INR measuring range from 0.8 to 8.0 with 97% accuracy when compared to lab results.^{19,20} INR extracted from the records included the INR reading at the first visit and INR reading by month for six months.

Data Analysis

Continuous variables were characterized by mean and standard deviation [SD] and by median and interquartile range [IQR]; categorical variables were characterized by frequencies and percentages. TTR was calculated using the Rosendaal linear interpolation method, which assumes there is a linear relationship between two consecutive INR results.²¹ This method determines the proportion of time for which the INR is within therapeutic range of 2.0 - 3.0. TTR was calculated by month for a period of six months with month defined as a scheduled visit at 28 to 30 days of last clinic visit. Wilcoxon Signed Rank test was used to compare median percentage TTR between months.

Patients returning to the clinic after 30 days were considered as missing scheduled visit. Spearman's rho coefficient was used to analyse association between number of missing visits and TTR.

Further analysis involved comparing the change in anticoagulation status of patients between month three and month six. These periods were used to compensate for missed patient visits. Where patients missed the three month or six month appointment the last TTR value was carried forward to determine anticoagulation status categorization. Patients missing two consecutive month visits were excluded from the analysis of anticoagulation status.

Using guidelines established by the University of Nottingham PRIMIS development group, patients were stratified into categories based on TTR as poor anticoagulation status (TTR<40%), moderate anticoagulation status (TTR of 40 to 64%) and good anticoagulation status (TTR \geq 65%). McNemar-Bowker pairwise Chi-Square test for proportions was used to compare anticoagulation status at month three and month six. For all inferential statistics done, statistical significance was considered as p values less than 0.05.

RESULTS

In total, the study identified 52 patient dockets meeting inclusion criteria and the demographics are presented in Table 1. Thirty-six (69.2 %) patients were males and the ages ranged from 23 to 90 years with a median age of 58 years. At the first visit to the clinic, the warfarin weekly doses ranged from a low of 15.0 mg to 85 mg; 9 (17.3%) patients presented with an INR within the target range; 24 (46.2%) patients were below target INR and 19 (36.5 %) patients were above target INR. The most common indication for warfarin therapy was deep vein thrombosis. During the first month the weekly dose of warfarin prescribed by the clinic range from a low of 17.5 mg to a high of 130.0 mg and varied over the five to six month period from a weekly low dose of 15.0 mg to a high of 110.0 mg. Over the six months of data collected, the records documented 30 patients as being fully compliant with dosing, while 12 patients dockets noted one to three times missing warfarin dose for the month; information documenting patient compliance was missing for 10 patients.

Of the total, 51 patients returned to the clinic within one month of the first visit with 40 (76.9%) patients attending the clinic two or more times in the first month. In terms of anticoagulation status, after one month, of the patients that were below target INR range at the first visit, 2/24 returned in good anticoagulation status, of those in target INR range, 4/9 returned in good anticoagulation status and of those above target INR range, 2/18 returned in good anticoagulation status. The mean and median TTR after one month were 36.5% (SD 30.1) and 31% [IQR 62-10], respectively (Table 1). Significant improvement in TTR was attained by the second month (54.2; SD 35.3 and 60 [IQR 82-23] respectively; p=0.001).

A total of 26 missed scheduled visits (of 312 visits; 8.3%) were recorded ranging from one patient in months one and

Table 1. Details of the 52 patients in study population			
	Num. patients	Mean (SD)	Median [IQR]
Gender			
Male	36		
Female	15		
Missing data	1		
Indication			
Deep vein thrombosis (DVT)	22		
Atrial fibrillation	18		
Pulmonary embolism (PE)	5		
DVT and PE	3		
DVT and Antiphospholipid syndrome	1		
Chronic venous insufficiency	1		
External rectal vein thrombosis	1		
Cardiovascular accident	1		
Age	52	59 (16.4)	58 [72-47]
Warfarin Weekly dose/mg (range: lowest-highest)			
At first visit (Range: 15.0-85.0)		38.1 (15.4)	37.5[42.5-30.0]
Month 1[Range:17.5-130.0]		55.0 (20.4)	52.5 [63.0-40.6]
Months 2-6 [Range:15.0-110.0]		46.8 (17.4)	44.0[57.5-35.5]
INR at first visit (<i>Target Range 2-3</i>)			
Below Target	24	1.46 (0.28)	1.47 (0.51)
Within Target	9	2.32 (0.25)	2.29 (0.27)
Above Target	19	4.48 (1.54)	3.59 (1.90)
TTR%			
Month 1	51	36.5 (30.1)	31 [52-10]
Month 2	51	54.2 (35.3)	60 [82-23]
Month 3	49	53.3 (35.0)	50 [93-21.5]
Month 4	47	53.4 (37.0)	51 [100-18]
Month 5	48	53.4 (39.7)	51.5 [100-15.5]
Month 6	40	56.4 (39.6)	52.5 [100-20.5]
Total number of missed visits =26			
SD=Standard Deviation; IQR=Interquartile Range; INR=International Normalized Ratio % TTR=Percentage time spent in therapeutic range			

two, three patients missing visits in month three, five patients in month four, 4 patients in month five and 12 patients in month six. No correlation was found between missed scheduled visits and median TTR by month. One patient missed two consecutive visits and was excluded from the assessment of anticoagulation status.

The change in anticoagulation status from month three to month six for the 51 remaining patients is displayed in Figure 1. At month three, 19 (37.3%) patients had good, 15 (29.4%) had moderate and 17 (33.3%) had poor anticoagulation status. Of those in good anticoagulation status at month three, 8/19 continued to remain in good anticoagulation status, while 7/19 presented with moderate and 4/19 deteriorated to poor anticoagulation status at month six. For patients moderate at month three, 6/15 improved to good anticoagulation status, 2/15 remained the same and 7/15 deteriorated to poor at month six. Of the seventeen patients that were in poor anticoagulation status at month three; there was improvement in TTR at month six for a greater proportion of the patients with 9/17 improved to good and 3/17 to moderate status; 5/17 remained in poor anticoagulation status. There was overall no significant improvement in the anticoagulated status of the patients from month 3 to month 6 (chi-square=3.60; degrees of freedom=3, p=0.31).

DISCUSSION

A six month assessment of the first established pharmacist managed anticoagulant clinic in Jamaica showed that overall the clinic was successful in achieving good

compliance with scheduled visits. In this study, the mean TTR obtained after one month was below values established as clinically adequate; but comparable with findings from other studies showing more time requirement.¹⁴ By the second month of therapy, the clinic was successful in maintaining monthly mean TTR in the range 53.4 % to 56.4%. The level of anticoagulation control obtained in this current setting is comparable with the meta-analysis study of Erkens, Cate, Büller and Prins, 2012, which reviewed forty randomized controlled and cohort studies of 26,064 similar patients published between January 1990 and May 2012.²² The mean TTR calculated from this meta-analysis ranged from 56% to 75%, with the higher percentage obtained when the first month was excluded from the calculations. Similar findings were reported in the systematic review by Manzoor *et al.*¹⁷

Furthermore, the study of Erkens *et al.*, proved that mean TTRs greater than 75 % were only observed after more than six months on warfarin. Therefore, while improvement in TTR was observed from month one to month three in the patients of this study, the absence of further improvement in patient anticoagulation status from month three to month six is consistent with the findings of Erkens *et al.*

The collection of the data for this study was limited by patients not attending scheduled visits, resulting in TTR values having to be carried forward for some patients. The measure of compliance with therapy was another limitation, as in some cases the information on missed dose was not available; furthermore patient recall over a month can be unreliable.




Figure 1. Change in anticoagulation status of patients on warfarin therapy from month three to month six; bars represent anticoagulation status at month six. At month three the proportions of patients in good, moderate and poor anticoagulation status were 19, 15, 17 respectively. By six months the proportions changed to 23, 12 and 16 respectively. With some patients improving and some deteriorating, the overall anticoagulation status remained the same from month three to month six (McNemar-Bowker pairwise chi-square=3.60; degrees of freedom=3; p=0.31).

CONCLUSIONS

In conclusion, the findings suggest that the monthly monitoring in this pharmacist managed clinic attained moderate to good anticoagulation status for most patients within three months and sustained for up to six months. The anticoagulation control is comparable to similar out-patient settings and such services have reported benefits to efficacy, safety and cost.^{17,23,24} Therefore, this pharmacist managed warfarin clinic services has the potential to facilitate better patient outcomes and should be supported.

CONFLICT OF INTEREST

Nothing to disclose.

FUNDING

The study received funds from the University of the West Indies to support transportation of Ms J McKenzie from Kingston to St James to collect data from the anticoagulation clinic.

References

1. McKenzie K, Campbell J, Procope A, Elliott V, Wilson-Clarke C, Gossell-Williams M. Therapeutic Anticoagulation Prevalence among Patients of a Cardiology Clinic receiving Warfarin and Association with Overweight. *Int J Pharmacovigilance*. 2016;1(1):1-4. doi: [10.15226/2476-2431/1/1/00101](https://doi.org/10.15226/2476-2431/1/1/00101)
2. Gong IY, Schwarz UI, Crown N, Dresser GK, Lazo-Langner A, Zou G, Roden DM, Stein CM, Rodger M, Wells PS, Kim RB, Tirona RG. Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. *PLoS One*. 2011;6(11):e27808. doi: [10.1371/journal.pone.0027808](https://doi.org/10.1371/journal.pone.0027808)
3. Roth JA, Boudreau D, Fujii MM, Farin FM, Rettie AE, Thummel KE, Veenstra DL. Genetic risk factors for major bleeding in patients treated with warfarin in a community setting. *Clin Pharmacol Ther*. 2014;95(6):636-643. doi: [10.1038/clpt.2014.26](https://doi.org/10.1038/clpt.2014.26)
4. Schapkaiz E, Sithole J. Predictors of warfarin dose requirements in South African patients attending an anticoagulation clinic. *J Vasc Nurs*. 2017;35(1):27-30. doi: [10.1016/j.jvn.2016.05.002](https://doi.org/10.1016/j.jvn.2016.05.002)
5. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D, Brandt JT. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. *Chest*. 1998;114(5):445S-469S. doi: [10.1378/chest.114.5_Supplement.445S](https://doi.org/10.1378/chest.114.5_Supplement.445S)
6. Vestergaard AS, Skjøth F, Larsen TB, Ehlers LH. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis. *PLoS One*. 2017;12(11):e0188482. doi: [10.1371/journal.pone.0188482](https://doi.org/10.1371/journal.pone.0188482)
7. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, Bankhead C, Xu Y. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation. *Circ Cardiovasc Qual Outcomes*. 2008;1(2):84-91. doi: [10.1161/CIRCOUTCOMES.108.796185](https://doi.org/10.1161/CIRCOUTCOMES.108.796185)
8. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. *Circulation*. 2008;118(20):2029-37. doi: [10.1161/CIRCULATIONAHA.107.750000](https://doi.org/10.1161/CIRCULATIONAHA.107.750000)

9. University of Nottingham PRIMIS Development Group. Warfarin Patient Safety Quality Improvement Tool. Available at: <https://www.nottingham.ac.uk/primis/documents/audit-docs/warfarin-patient-safety-quick-guide.pdf> (accessed August 18, 2018).
10. National Institutes for Health and Care Excellence. Atrial fibrillation: the management of atrial fibrillation: Clinical guideline 180. Available from: <https://www.nice.org.uk/guidance/CG180> . (accessed August 18, 2018).
11. Robinson J, Oliver K. Warfarin Patient Safety: free analysis tool for GP practices. *Prescriber*. 2014;25(13-16):33-34.
12. Nichol MB, Knight TK, Dow T, Wygant G, Borok G, Hauch O, O'Connor R. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care. *Ann Pharmacother*. 2008;42(1):62-70. doi: [10.1345/aph.1K157](https://doi.org/10.1345/aph.1K157)
13. Njaastad AM, Abildgaard U, Lassen JF. Gains and losses of warfarin therapy as performed in an anticoagulation clinic. *J Intern Med*. 2006;259(3):296-304. doi: [10.1111/j.1365-2796.2005.01605.x](https://doi.org/10.1111/j.1365-2796.2005.01605.x)
14. Rose AJ, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial fibrillation in community-based practise. *J Thromb Haemost*. 2008;6(10):1647-1654.
15. Kılıç S, Soner Kemal H, Yüce Eİ, Şimşek E, Yağmur B, Memişoğlu Akgül N, Soydaş Çınar C, Zoghi M, Gürgün C. Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics. *Anatol J Cardiol*. 2017;18(5):328-333. doi: [10.14744/AnatolJCardiol.2017.7886](https://doi.org/10.14744/AnatolJCardiol.2017.7886)
16. Bishop MA, Streiff MB. Effects of anticoagulation provider continuity on time in therapeutic range for warfarin patients. *J Thromb Thrombolysis*. 2016;42(2):283-287. doi: [10.1007/s11239-016-1359-y](https://doi.org/10.1007/s11239-016-1359-y)
17. Manzoor BS, Cheng W-H, Lee JC, Uppuluri EM, Nutescu EA. Quality of pharmacist-managed anticoagulation therapy in long-term ambulatory settings: A systematic review. *Ann Pharmacother*. 2017;51(12):1122-1137. doi: [10.1177/1060028017721241](https://doi.org/10.1177/1060028017721241)
18. Rose AJ, Reisman JI, Razouki Z, Ozonoff A. Percent time in range with warfarin as a performance measure: how long a sampling frame is needed? *Jt Comm J Qual Patient Saf*. 2015;41(12):561-568. doi: [10.1016/S1553-7250\(15\)41073-6](https://doi.org/10.1016/S1553-7250(15)41073-6)
19. Plesch W, Van den Besselaar A. Validation of the international normalized ratio (INR) in a new point-of-care system designed for home monitoring of oral anticoagulation therapy. *Int J Lab Hematol*. 2009;31(1):20-25. doi: [10.1111/j.1751-553X.2007.00998.x](https://doi.org/10.1111/j.1751-553X.2007.00998.x)
20. Bereznicki LR, Jackson SL, Peterson GM, Jeffrey EC, Marsden KA, Jupe DM. Accuracy and clinical utility of the CoaguChek XS portable international normalised ratio monitor in a pilot study of warfarin home-monitoring. *J Clin Pathol*. 2007;60(3):311-314. doi: [10.1136/jcp.2006.037820](https://doi.org/10.1136/jcp.2006.037820)
21. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. *Thromb Haemost*. 1993;69(3):236-239.
22. Erkens PM, ten Cate H, Büller HR, Prins MH. Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. *PLoS One*. 2012;7(9):e42269. doi: [10.1371/journal.pone.0042269](https://doi.org/10.1371/journal.pone.0042269)
23. Aidit S, Soh YC, Yap CS, Khan TM, Neoh CF, Shaharuddin S, Kassab YW, Patel RP, Ming LC. Effect of standardized warfarin treatment protocol on anticoagulant effect: comparison of a warfarin medication therapy adherence clinic with usual medical care. *Front Pharmacol*. 2017;8:637. doi: [10.3389/fphar.2017.00637](https://doi.org/10.3389/fphar.2017.00637)
24. Chang JY, Wang CC, Kang HC, Shen LJ, Huang CF. Cost-effectiveness of the pharmacist-assisted warfarin monitoring program at a Medical Center in Taiwan. *Int J Qual Health Care*. 2017;29(6):817-825. doi: [10.1093/intqhc/mzx109](https://doi.org/10.1093/intqhc/mzx109)